EvodiaBio, a Danish biotech company specializing in sustainable aroma molecule production, raised EUR 6 million in a funding round led by U.S.-based RA Capital. Existing investors, including EIFO, continued their support, while new international backers such as Wild Radicals and Francis Family Funds joined. The funding will accelerate growth in Europe, North America, and prepare the company for expansion into Asia.
EvodiaBio has developed a technology platform enabling industrial-scale production of volatile aroma molecules more efficiently and sustainably than traditional methods, with applications in beer, beverages, and the broader aroma industry. The company moved from research to industrial production in just a few years, removing major technological and commercial risks and achieving documented market demand.
“This investment puts us in a position to scale globally. I am proud of our team – within just three and a half years, we have gone from a research project to industrial production with all necessary approvals and a profitable product. That is rarely seen in the biotech industry. This investment enables us to accelerate global growth and realize our ambition of becoming a Danish unicorn in industrial biotech,” said Camilla Kloss Fenneberg, CEO of EvodiaBio.
Since its launch earlier this year, EvodiaBio has achieved global commercial traction with more than 70 commercial brews and over 10 projects with top-40 breweries. The technology has demonstrated the potential to transform beer production and reduce reliance on hops, a raw material threatened by climate change.
“RA Capital’s investment in EvodiaBio at this stage underscores the company’s strong position. It confirms that we have removed the key risks related to technology, production, and commercialization. We have proven that the technology works, that customers are interested in the product, and that the business model has been profitable from day one. Now we are ready to accelerate growth,” said Jarne Elleholm, Chairman of the Board at EvodiaBio.
With the latest funding, EvodiaBio plans further expansion into Asia and new industries including wine and other beverage categories, leveraging its sustainable and efficient technology to become a global leader in industrial biotech. The round marks the company’s third fundraising in three years, bringing total capital raised to DKK 150 million.